Idexx Laboratories (IDXX) Cash from Financing Activities (2009 - 2026)

Idexx Laboratories' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$211.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 35.99% year-over-year to -$211.4 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 1.71% YoY), while the FY2025 annual figure was -$1.2 billion, down 32.67% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$211.4 million, up from -$355.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was -$13.5 million in Q1 2022, with the low at -$355.7 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is -$151.0 million (2023), against an average of -$180.4 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 89.6% in 2022, then plunged 983.69% in 2023.
• Idexx Laboratories' Cash from Financing Activities stood at -$116.7 million in 2022, then increased by 12.75% to -$101.8 million in 2023, then slumped by 128.57% to -$232.8 million in 2024, then tumbled by 52.8% to -$355.7 million in 2025, then surged by 40.56% to -$211.4 million in 2026.
• Business Quant data shows IDXX's Cash from Financing Activities at -$211.4 million in Q1 2026, -$355.7 million in Q4 2025, and -$313.3 million in Q3 2025.